Smith & Nephew PLC (SN.L)

SN.L on London Stock Exchange

982.00GBp
9:06am EDT
Price Change (% chg)

-8.50p (-0.86%)
Prev Close
990.50p
Open
990.00p
Day's High
994.00p
Day's Low
978.50p
Volume
714,846
Avg. Vol
2,372,586
52-wk High
1,136.00p
52-wk Low
780.50p

SN.L

Chart for SN.L

About

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. It... (more)

Overall

Beta: 0.55
Market Cap (Mil.): £8,862.72
Shares Outstanding (Mil.): 893.54
Dividend: 6.85
Yield (%): 1.73

Financials

  SN.L Industry Sector
P/E (TTM): 27.36 31.87 33.86
EPS (TTM): 0.36 -- --
ROI: 9.38 8.73 17.53
ROE: 12.99 12.03 18.34
Search Stocks

Smith & Nephew 'spray-on-skin' for leg ulcers flops in trial

LONDON - A novel spray-on skin treatment consisting of living cells made by Smith & Nephew, which is designed to work with the body’s own cells to help heal leg ulcers, has failed in a late-stage clinical trial.

13 Oct 2014

UPDATE 1-Smith & Nephew "spray-on-skin" for leg ulcers flops in trial

* Shares fall 1.2 percent (Adds analyst comments, shares)

13 Oct 2014

Smith & Nephew spray-on cell therapy flops in trial

LONDON, Oct 13 - A novel spray-on treatment consisting of living cells made by Smith & Nephew, which is designed to work with the body's own cells to help heal leg ulcers, has failed in a late-stage clinical trial.

13 Oct 2014

BRIEF-Smith & Nephew ulcer therapy fails to meet primary endpoint

* Second phase 3 study in European Union, which is expected to report in 2016, will continue while programme analysis is completed Source text for Eikon: Further company coverage:

13 Oct 2014

BRIEF-Smith & Nephew says NYSE-listed ADRs to be split

* Announces an intended ratio change to its nyse-listed american depositary receipt ("ADR") programme

24 Sep 2014

REPEAT-UPDATE 2-AstraZeneca, Shire dive as U.S. tax move punctures deal hopes

* Seen as possible threat to Shire's agreed sale to AbbVie

23 Sep 2014

Pharma shares knock FTSE as new U.S. tax rules dent M&A hopes

LONDON, Sept 23 - Britain's top shares fell on Tuesday, dragged down by healthcare shares as new U.S. tax rules dented the takeover appeal of companies such as Shire and AstraZeneca.

23 Sep 2014

Smith & Nephew to pay $11 mln in whistleblower suit

Sept 4 - London-based medical device maker Smith & Nephew PLC has agreed to pay $11.3 million to settle allegations that it sold the U.S. government devices it claimed were U.S.-made but actually came from Malaysia.

04 Sep 2014

UK's FTSE flops as financials fall

LONDON, Aug 1 - Financial stocks underperformed as Britain's top equity index fell to a three-week low on Friday, while weak UK manufacturing data also weighed on the market.

01 Aug 2014

Smith & Nephew sees more sector deals, not under investor pressure

LONDON - Smith & Nephew (S&N), Europe's largest maker of artificial joints, expects continued deal-making in the medical technology sector but has not come under pressure from investors to sell out, its chief executive said on Friday.

01 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$115.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks